



**MATERIAL SAFETY DATA SHEET**  
**CHLORPROMAZINE MIXTURE 25mg/5mL**

Page 1:4

**1. Identification of the Product and Company**

<b>Product Name:</b>	<b>CHLORPROMAZINE MIXTURE 25mg/5mL</b>
<b>Product Code:</b>	CHL01376F
<b>Other Names:</b>	None allocated
<b>Use:</b>	Major tranquilliser. Used in the treatment of psychosis including schizophrenia and mania. It is also used for the management of anxiety, tension, agitation and for the relief of nausea and vomiting.
<b>Company Name &amp; Contact Details</b>	Drug Information Pharmacist ORION Laboratories Pty Ltd ABN 56 009 293 136 25-29 Delawney Street, Balcatta, Western Australia 6021 AUSTRALIA <b>Telephone (all hours): +618 9441 7800</b> FREE PHONE: 1800 805 546 FREE FAX: 1800 004 110 EMAIL: customerservice@orion.net.au; WEBSITE: www.orion.net.au ORION® is a registered trademark of Orion Laboratories Pty Ltd
<b>Other Information</b>	All reasonable care has been taken to ensure information and advice contained in this data sheet is accurate at time of printing. However, Orion accepts no liability for any loss or damages suffered as a consequence of reliance on the information contained herein.

**2. Hazards Identification**

<b>Hazard Classification</b>	This product is not hazardous or dangerous
<b>Risk phrase(s)</b>	No component is present at sufficient concentration to require a hazardous classification
<b>Safety phrase(s)</b>	This medication may cause drowsiness. If affected do not drive a vehicle or operate machinery. Avoid alcohol Avoid skin contact. Chlorpromazine may cause dermatitis.

**3. Composition/Information on Ingredients**

<b>Chemical Entity</b>	<b>CAS No:</b>	<b>Proportion</b>
Chlorpromazine Hydrochloride	69-09-0	< 10%
Saccharin Sodium	-	< 10%
Chloroform	67-66-3	< 10%
Ethanol 95%	64-17-5	< 10%
Glycerol	56-81-5	10 - 30%
Sorbitol Solution 70%	50-70-4	10 - 30%
Citric Acid (anhydrous)	77-92-9	< 10%
Ascorbic Acid	50-81-7	< 10%
Flavour	-	< 10%
Water, Purified	7732-18-5	to 100%

<b>4. First Aid Measures</b>	<b>In case of accidental overdose/poisoning, take patient to hospital.</b>
<b>Inhalation:</b>	Not expected to cause problems.
<b>Ingestion:</b>	May lead to reduced mental alertness, dry mouth, blurred vision, tremor, sleepiness, seizures, urinary retention, fast or irregular heart beat, low blood pressure, high or low body temperature, dilated or constricted pupils.
<b>Skin:</b>	May be irritating to the skin, causing contact dermatitis. Hypersensitivity reactions have been reported.
<b>Eye:</b>	May be irritating to the eyes causing redness and soreness.
<b>Advice to Doctor:</b>	<p>The symptoms of overdosage with chlorpromazine include CNS depression progressing from drowsiness to coma with areflexia; patients with early or mild intoxication may experience restlessness, confusion and excitement. Other symptoms include hypotension, tachycardia, hypothermia, pupillary constriction, tremor, muscle twitching, spasm or rigidity, convulsions, muscle hypotonia, difficulty in swallowing and breathing, cyanosis and respiratory and/or vasomotor collapse, possibly with sudden apnoea. Polyuria has also been noted, which may result in dehydration.</p> <p>Deaths in young children have followed ingestion of chlorpromazine 350 to 800mg.</p> <p>Emetics should not be used - chlorpromazine has antiemetic properties &amp; sedative and extrapyramidal side effects increase the risk of pulmonary aspiration should vomiting occur.</p> <p><i>Acute Hypotension:</i> Place patient in head down position and administer noradrenaline or phenylephrine intravenously. Adrenaline is contraindicated.</p> <p><i>Central Nervous System Depression:</i> Allow patient to recover naturally, though artificial respiration may be required. Antibiotic therapy may be administered for any respiratory infections.</p> <p><i>Hypothermia:</i> Monitor body temperature and allow patient to recover naturally unless the temperature approaches levels at which cardiac arrhythmias may occur (e.g. 29.4°C). Shivering is a sign of waning drug effects.</p> <p>Severe extrapyramidal reactions should be treated with bztropine or other antiparkinsonian agent (intramuscular dose in adults: 1 to 2mg, children 0.2 to 0.25mg initially with increments if necessary.</p>

<b>5. Fire Fighting Measures</b>	
<b>Extinguishing Media</b>	The following may be used in case of fire: Water jets/fog, dry chemical agents, alcohol stable foam.
<b>Hazards from Combustion products</b>	Toxic decomposition products are expected when the product is exposed to fire.
<b>Precautions &amp; Equipment for Fire Fighters</b>	Special equipment is not necessary, though fire-fighters should wear breathing apparatus in case of exposure to toxic by-products.
<b>Hazchem Code</b>	None allocated

<b>6. Accidental Release Measure</b>	
	Contain using an absorbent (sand, sawdust, vermiculite) where appropriate. Collect and seal in properly labelled containers for disposal. Wash area down with excess water.
	Waste material may be incinerated under controlled conditions where permitted. Refer to local Waste Management Authority Regulations for other approved methods.

## 7. Handling and Storage

<b>Safe Handling Practices</b>	Avoid skin contact.
<b>Storage</b>	Store below 25°C and protect from light. Store away from food stuff
<b>Other Information</b>	Not hazardous for the purposes of transport and storage.

## 8. Exposure Controls; Personal Protection

<b>Exposure Limits:</b>	No data available
<b>Engineering Controls</b>	No data available.
<b>Personal Protection</b>	No data available. Wash hands after use

## 9. Physical and Chemical Properties

<b>Appearance / Odour:</b>	A clear, colourless or slightly yellow liquid, having a peppermint odour and flavour.
<b>pH:</b>	2 - 3
<b>Vapour Pressure:</b>	Not known
<b>Vapour Density:</b>	Not known
<b>Boiling Point:</b>	Not known
<b>Freezing/Melting Point:</b>	Not known
<b>Solubility:</b>	Miscible in water
<b>Specific Gravity or Density:</b>	1.10 - 1.12 g/mL

## 10. Chemical Stability and Reactivity Information

<b>Conditions Contributing to Instability</b>	This product is expected to be stable.
<b>Conditions to Avoid:</b>	None for normal handling of this product.

## 11. Toxicological Information

<b>Inhalation:</b>	Not expected to cause problems.
<b>Ingestion:</b>	May lead to reduced mental alertness, dry mouth, blurred vision, tremor, sleepiness, seizures, urinary retention, fast or irregular heart beat, low blood pressure, high or low body temperature, dilated or constricted pupils.
<b>Skin:</b>	May be irritating to the skin, causing contact dermatitis. Hypersensitivity reactions have been reported.
<b>Eye:</b>	May be irritating to the eyes causing redness and soreness.

**12. Ecological Information**

**Mobility:** Information is not available about the potential of this product to produce adverse environmental effects.

**13. Disposal Considerations**

**Disposal Methods & Containers:** Special requirements have not been identified. Waste material may be incinerated under controlled conditions where permitted.  
**Special Disposal for Landfill or Incineration:** Refer to local Waste Management Authority Regulations for other approved methods.

**14. Transport Information Not hazardous for the purposes of transport and storage.**

**UN Number:** None allocated  
**UN Proper Shipping Name:** None allocated  
**DG Class & Subsidiary Risk:** None allocated  
**Packing Group:** None allocated  
**Hazchem Code:** None allocated

**15. Regulatory Information**

Prescription only medicine (S4)

**16. Other Information**

- References:**
- *MSDS Chlorpromazine Hydrochloride 11/01/2010 Science Lab.com*
  - *PI Chlorpromazine Mixture and Chlorpromazine Mixture Forte CHL01376\_1\_PI Orion Laboratories*

Checked by: Anna McLean	Date: October 2011
Approved by: Robert Kimpton	Date: October 2011

<b>Revision Information</b>			
Date	Document Name	Superseded Document	Revision Information
August 2005	CHL00764S_04	CHL00764S_3	General review
August 2008	CHL00764S_05	CHL00764S_04	General review
October 2011	CHL00764S_06	CHL00764S_05	General review
	October 2011	August 2008	

END OF MSDS